ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

RIGL vs SVRA // PIOTROSKI F-SCORE QUALITY

Rigel Pharmaceuticals Inc. (NASDAQ) VS. Savara Inc. (NASDAQ) • 15-METRIC TALLY: RIGL 4 — SVRA 1
▲ PIOTROSKI F-SCORE QUALITY LEADER: RIGL
piotroski-score
7/9
piotroski-score
3/9
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (RIGL VS. SVRA) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC RIGL SVRA SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin 93.30% — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) 28.20% -35.00% +63.20 RIGL /roic <GO>
EV/EBITDA & P/E Valuation 7.3x — — TIE /valuation <GO>
Free Cash Flow Yield 7.87% -9.94% +17.81 RIGL /fcf-yield <GO>
Operating Margin 42.60% — — TIE /operating-margins <GO>
Net Profit Margin 68.00% — — TIE /net-margins <GO>
Revenue Growth (YoY) 64.10% — — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity 3.64 — — TIE /balance-sheet <GO>
Piotroski F-Score Quality ACTIVE 7/9 3/9 +4.00 RIGL /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 64.4 49.3 +15.06 RIGL /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $961.1M $1.02B -$55.9M SVRA /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR RIGL REV SVRA REV RIGL GROSS % SVRA GROSS % RIGL FCF SVRA FCF
FY 2025 $294.3M $0 93.3% — $75.7M -$101.1M
FY 2024 $179.3M $0 89.6% — $31.5M -$89.1M
FY 2023 $116.9M $0 — — -$5.7M -$51.1M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
RIGL // BETA —
SVRA // BETA —